BEYOND CREATININE: THE ROLE OF EMERGING BIOMARKERS IN EARLY DETECTION OF ACUTE KIDNEY INJURY IN ADULTS: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6620Keywords:
Acute Kidney Injury, AKI Biomarkers, NGAL, KIM-1, TIMP-2, IGFBP7Abstract
Acute kidney injury (AKI) is a common clinical syndrome associated with increased morbidity, mortality, length of hospitalization, and long-term risk of chronic kidney disease. In routine practice, AKI is still diagnosed primarily by changes in serum creatinine concentration and urine output. Although these criteria are standardized and clinically useful, they are imperfect markers of early kidney injury because creatinine rises only after a fall in filtration has occurred and urine output is influenced by hemodynamics, medications, fluid balance, and measurement accuracy. This systematic literature review evaluates the role of emerging biomarkers in the early detection and risk stratification of AKI in adults, with particular emphasis on neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18), liver-type fatty acid-binding protein (L-FABP), cystatin C, and the cell-cycle arrest biomarker combination tissue inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein 7 ([TIMP-2]*[IGFBP7]). The reviewed literature suggests that biomarkers may identify tubular stress or injury earlier than conventional criteria, support risk stratification in selected high-risk populations, and help distinguish functional decline from structural damage. However, heterogeneity of populations, assay platforms, timing of sampling, thresholds, and reference standards limits routine implementation. Biomarkers are best understood as adjuncts to clinical assessment rather than replacements for standard diagnostic criteria.
References
Bihorac, A., Chawla, L. S., Shaw, A. D., et al. (2014). Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. American Journal of Respiratory and Critical Care Medicine, 189(8), 932–939. https://doi.org/10.1164/rccm.201401-0077OC
Hoste, E. A. J., Bagshaw, S. M., Bellomo, R., Cely, C. M., Colman, R., Cruz, D. N., et al. (2015). Epidemiology of acute kidney injury in critically ill patients: The multinational AKI-EPI study. Intensive Care Medicine, 41(8), 1411–1423. https://doi.org/10.1007/s00134-015-3934-7
Kashani, K., Al-Khafaji, A., Ardiles, T., et al. (2013). Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Critical Care, 17(1), R25. https://doi.org/10.1186/cc12503
Kellum, J. A., & Lameire, N., for the KDIGO AKI Guideline Work Group. (2013). Diagnosis, evaluation, and management of acute kidney injury: A KDIGO summary (Part 1). Critical Care, 17(1), 204. https://doi.org/10.1186/cc11454
Meersch, M., Schmidt, C., Hoffmeier, A., et al. (2017). Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: The PrevAKI randomized controlled trial. Intensive Care Medicine, 43(11), 1551–1561. https://doi.org/10.1007/s00134-016-4670-3
Ostermann, M., Zarbock, A., Goldstein, S., Kashani, K., Macedo, E., Murugan, R., et al. (2020). Recommendations on acute kidney injury biomarkers from the Acute Disease Quality Initiative Consensus Conference: A consensus statement. JAMA Network Open, 3(10), e2019209. https://doi.org/10.1001/jamanetworkopen.2020.19209
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71
Pan, H. C., Yang, S. Y., Chiou, T. T. Y., Shiao, C. C., Wu, C. H., Huang, C. T., et al. (2022). Comparative accuracy of biomarkers for the prediction of hospital-acquired acute kidney injury: A systematic review and meta-analysis. Critical Care, 26(1), 349. https://doi.org/10.1186/s13054-022-04223-6
Parikh, C. R., Devarajan, P., Zappitelli, M., Sint, K., Thiessen-Philbrook, H., Li, S., et al. (2011). Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. Journal of the American Society of Nephrology, 22(9), 1748–1757. https://doi.org/10.1681/ASN.2010121302
Ronco, C., Bellomo, R., & Kellum, J. A. (2019). Acute kidney injury. The Lancet, 394(10212), 1949–1964. https://doi.org/10.1016/S0140-6736(19)32563-2
Zarbock, A., Küllmar, M., Ostermann, M., Lucchese, G., Baig, K., Cennamo, A., et al. (2021). Prevention of cardiac surgery-associated acute kidney injury by implementing the KDIGO guidelines in high-risk patients identified by biomarkers: The PrevAKI-Multicenter randomized controlled trial. Anesthesia & Analgesia, 133(2), 292–302. https://doi.org/10.1213/ANE.0000000000005458
Chawla, L. S., Bellomo, R., Bihorac, A., et al. (2017). Acute kidney disease and renal recovery: Consensus report of the Acute Disease Quality Initiative 16 workgroup. Nature Reviews Nephrology, 13(4), 241–257. https://doi.org/10.1038/nrneph.2017.2
Pickkers, P., Darmon, M., Hoste, E., et al. (2021). Acute kidney injury in the critically ill: An updated review on pathophysiology and management. Intensive Care Medicine, 47, 835–850. https://pubmed.ncbi.nlm.nih.gov/34216237/
Gameiro, J., Fonseca, J. A., Outerelo, C., & Lopes, J. A. (2020). Acute kidney injury: From diagnosis to prevention and treatment strategies. Journal of Clinical Medicine, 9(6), 1704. https://doi.org/10.3390/jcm9061704
Vijayan, A., Faubel, S., Askenazi, D. J., et al. (2016). Clinical use of the urine biomarker [TIMP-2] x [IGFBP7] for acute kidney injury risk assessment. American Journal of Kidney Diseases, 68(1), 19–28. https://doi.org/10.1053/j.ajkd.2015.12.033
Basu, R. K., & Kaddourah, A. (2022). Improving acute kidney injury diagnostic precision using biomarkers. Frontiers in Pediatrics, 10, 818739. https://doi.org/10.3389/fped.2022.818739
Srisawat, N., Sileanu, F. E., Murugan, R., et al. (2015). Variation in risk and mortality of acute kidney injury in critically ill patients: A multicenter study. American Journal of Nephrology, 41(1), 81–88. https://doi.org/10.1159/000371748
Vanmassenhove, J., Van Biesen, W., & Vanholder, R. (2017). Subclinical AKI: Ready for primetime in clinical practice? Journal of Nephrology, 32, 9–16. https://pubmed.ncbi.nlm.nih.gov/29159713/
Macedo, E., Mehta, R. L., & Prasad, N. (2022). Biomarkers for early detection and predicting outcomes in acute kidney injury. British Journal of Hospital Medicine, 83(9), 1–11. https://doi.org/10.12968/hmed.2022.0032
Pan, H. C., Chien, Y. S., Jenq, C. C., et al. (2024). Persistent acute kidney injury biomarkers: A systematic review and meta-analysis. Critical Care, 28, 214. https://pubmed.ncbi.nlm.nih.gov/39127297/
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Maciej Krzesimir Kuświk, Wojciech Sontag, Julia Gawlak, Zofia Tarnawska, Karolina Figiel, Mateusz Gawin, Emilia Koziara, Mateusz Gadzina, Mateusz Zawisza, Aleksandra Golec
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
